83 results
Page 3 of 5
8-K
EX-99.1
3j0ocdkb3wmdv6z t85y
18 May 23
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
8:40am
8-K
EX-10.1
fkmdeng ix
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
xvalm4sfd
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
9odu7hso64a0
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
lh8dh
8 May 23
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:13pm
10-K/A
3ntws4e575labovy
28 Apr 23
Annual report (amended)
4:15pm
8-K
EX-99.1
tq2y37 o0brjv5ytq8i
18 Apr 23
ZW191 demonstrates strong responses in FRĪ±-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles
4:18pm
8-K
EX-99.1
j0v60z
10 Apr 23
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
4:46pm
8-K
EX-99.1
jszxn0h
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
8:37am
8-K
EX-99.1
x52ht tnm
19 Dec 22
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
7:15am
8-K
EX-99.1
hera5sne fye
9 Dec 22
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
4:31pm
8-K
EX-99.1
x5ogfzsa o2
5 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:39am
8-K
EX-99.1
zo1v4a2 r77rdp3qk3
29 Nov 22
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
4:30pm
DEF 14A
uy61mpu0k2dr dwx
25 Nov 22
Definitive proxy
6:16am
8-K
EX-1.1
7u7qz9eyvo75f76
9 Nov 22
Entry into a Material Definitive Agreement
4:50pm
424B5
2ik6ckh
9 Nov 22
Prospectus supplement for primary offering
4:29pm
8-K
EX-99.1
i7x9x
8 Nov 22
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:19pm